Acetyl salicylic acid |
50-78-2 |
Salicylate |
Non-steroidal anti-inflammatory drug (NSAID) |
10, 100, 500, 1000, 1500, and 2000 μM |
99.9% |
Sigma Aldrich |
Powder |
Erlotinib |
183319-69-9 |
Quinazoline |
HER1/EGFR tyrosine kinase inhibitor |
0.0005, 0.001, 0.01, 0.1, 1, 10, 25, and 50 μM |
99.9% |
Roche Diagnostics |
Powder |
Levamisole |
16595-80-5 |
Imidazothiazole |
Alkaline phosphatase inhibitor |
0.01, 0.1, 1, 10, 50, 100, 250, 500, 750, 1000, and 2000 μM |
99% |
Sigma Aldrich |
Powder |
2-Methoxyestradiol |
363-07-2 |
Estradiol metabolite |
Tubulin inhibitor |
0.01, 0.1, 0.2, 0.4, 0.6 0.8, 1, and 2 μM |
99.5% |
Sigma Aldrich |
Powder |
|
Thalidomide |
50-35-1 |
Phthalimide |
Immunomodulator, TNF-α inhibitor |
10, 100, 200, 300, 400, and 500 μM |
>99% |
Sigma Aldrich |
Powder |
Anti-VEGF |
n/a |
Human VEGF165 and VEGF121 antibody, IgG fraction of antiserum |
Growth factor antibody |
0.5, 1, 2.5, 5, 7.5, 10, 25, and 50 μg/ml |
n/a |
Sigma Aldrich |
Lyophilized powder |